Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Vaxcyte Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, indicating separate examination settings within the portfolio.
SHOMER, ISAAC is the busiest examiner, with 1 pending matter. Counsel should preserve a matter-specific strategy while considering whether shared biotechnology issues support consistent positions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.1% | +30.3% |
| GRASER, JENNIFER E | 1 | 76.9% | +23.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18591479 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | SHOMER, ISAAC | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18591479 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | SHOMER, ISAAC | 12d |
| 18447146 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | GRASER, JENNIFER E | 15d |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18591479 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | SHOMER, ISAAC | 1612 | §102§103§112 | Non-Final OA | 12d | Pending | Feb 29, 2024 |
| 18447146 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | GRASER, JENNIFER E | 1645 | §103§112DP | Non-Final OA | 15d | Pending | Aug 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVaxcyte Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Isaac Shomer has the most, with 1 of Vaxcyte Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.